Renal ischemia regulates marinobufagenin release in humans

Hypertension

Volumn 56, Issue 5, 2010, Pages 914-919

  Tian, Jiang ^a   Haller, Steven ^a   Periyasamy, Sankaridrug ^a   Brewster, Pamela ^a   Zhang, Haifeng ^a   Adlakha, Satjit ^a   Fedorova, Olga V ^b   Xie, Zi Jian ^a   Bagrov, Alexei Y ^b   Shapiro, Joseph I ^a   Cooper, Christopher J ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

cardiotonic steroids; hypertension; marinobufagenin; renal artery stenosis; renal artery stenting

Indexed keywords

MARINOBUFAGENIN; BUFADIENOLIDE DERIVATIVE;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; KIDNEY ARTERY STENOSIS; KIDNEY ISCHEMIA; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RENAL PROTECTION; REVASCULARIZATION; STENT; AGED; ANALYSIS OF VARIANCE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; GLOMERULUS FILTRATION RATE; HYPERTENSION; ISCHEMIA; KIDNEY; MIDDLE AGED; PATIENT SELECTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; VASCULARIZATION;

AGED; ANALYSIS OF VARIANCE; BUFANOLIDES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; ISCHEMIA; KIDNEY; LOGISTIC MODELS; MALE; MIDDLE AGED; PATIENT SELECTION; PROSPECTIVE STUDIES; RENAL ARTERY OBSTRUCTION; STENTS;

EID: 78149256883     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.155564     Document Type: Article

References (49)

1. Schoner W, Scheiner-Bobis G. Role of endogenous cardiotonic steroids in sodium homeostasis. Nephrol Dial Transplant. 2008;23:2723-2729.
2. Komiyama Y, Dong XH, Nishimura N, Masaki H, Yoshika M, Masuda M, Takahashi H. A novel endogenous digitalis, telocinobufagin, exhibits elevated plasma levels in patients with terminal renal failure. Clin Biochem. 2005;38:36-45.
3. Komiyama Y, Nishimura N, Munakata M, Mori T, Okuda K, Nishino N, Hirose S, Kosaka C, Masuda M, Takahashi H. Identification of endogenous ouabain in culture supernatant of PC12 cells. J Hypertens. 2001;19:229-236.
4. Bagrov AY, Fedorova OV, Dmitrieva RI, Howald WN, Hunter AP, Kuznetsova EA, Shpen VM. Characterization of a urinary bufodienolide Na +, K +-ATPase inhibitor in patients after acute myocardial infarction. Hypertension. 1998;31:1097-1103.
5. Laredo J, Hamilton BP, Hamlyn JM. Ouabain is secreted by bovine adrenocortical cells. Endocrinology. 1994;135:794-797.
6. Laredo J, Shah JR, Lu ZR, Hamilton BP, Hamlyn JM. Angiotensin II stimulates secretion of endogenous ouabain from bovine adrenocortical cells via angiotensin type 2 receptors. Hypertension. 1997;29:401-407.
7. Fedorova OV, Anderson DE, Bagrov AY. Plasma marinobufagenin-like and ouabain-like immunoreactivity in adrenocorticotropin-treated rats. Am J Hypertens. 1998;11:796-802.
8. Bauer N, Muller-Ehmsen J, Kramer U, Hambarchian N, Zobel C, Schwinger RH, Neu H, Kirch U, Grunbaum EG, Schoner W. Ouabain-like compound changes rapidly on physical exercise in humans and dogs: effects of β-blockade and angiotensin-converting enzyme inhibition. Hypertension. 2005;45:1024-1028.
9. De Angelis C, Haupert GT Jr. Hypoxia triggers release of an endogenous inhibitor of Na (+)-K (+)-ATPase from midbrain and adrenal. Am J Physiol. 1998;274:F182-F188.
10. Weidemann H, Salomon N, Avnit-Sagi T, Weidenfeld J, Rosen H, Lichtstein D. Diverse effects of stress and additional adrenocorticotropic hormone on digitalis-like compounds in normal and nude mice. J Neuroendocrinol. 2004;16:458-463.
11. Derkx FH, Schalekamp MA. Renal artery stenosis and hypertension. Lancet. 1994;344:237-239.
12. Davis BA, Crook JE, Vestal RE, Oates JA. Prevalence of renovascular hypertension in patients with grade III or IV hypertensive retinopathy. N Engl J Med. 1979;301:1273-1276.
13. Losito A, Fagugli RM, Zampi I, Parente B, de Rango P, Giordano G, Cao P. Comparison of target organ damage in renovascular and essential hypertension. Am J Hypertens. 1996;9:1062-1067.
14. Simon N, Franklin SS, Bleifer KH, Maxwell MH. Clinical characteristics of renovascular hypertension. JAMA. 1972;220:1209-1218.
15. Lopatin DA, Ailamazian EK, Dmitrieva RI, Shpen VM, Fedorova OV, Doris PA, Bagrov AY. Circulating bufodienolide and cardenolide sodium pump inhibitors in preeclampsia. J Hypertens. 1999;17:1179-1187.
16. Vu HV, Ianosi-Irimie MR, Pridjian CA, Whitbred JM, Durst JM, Bagrov AY, Fedorova OV, Pridjian G, Puschett JB. Involvement of marinobufagenin in a rat model of human preeclampsia. Am J Nephrol. 2005;25:520-528.
17. Kennedy DJ, Vetteth S, Periyasamy SM, Kanj M, Fedorova L, Khouri S, Kahaleh MB, Xie Z, Malhotra D, Kolodkin NI, Lakatta EG, Fedorova OV, Bagrov AY, Shapiro JI. Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy. Hypertension. 2006;47:488-495.
18. Elkareh J, Kennedy DJ, Yashaswi B, Vetteth S, Shidyak A, Kim EG, Smaili S, Periyasamy SM, Hariri IM, Fedorova L, Liu J, Wu L, Kahaleh MB, Xie Z, Malhotra D, Fedorova OV, Kashkin VA, Bagrov AY, Shapiro JI. Marinobufagenin stimulates fibroblast collagen production and causes fibrosis in experimental uremic cardiomyopathy. Hypertension. 2007;49:215-224.
19. Kennedy DJ, Elkareh J, Shidyak A, Shapiro AP, Smaili S, Mutgi K, Gupta S, Tian J, Morgan E, Khouri S, Cooper CJ, Periyasamy SM, Xie Z, Malhotra D, Fedorova OV, Bagrov AY, Shapiro JI. Partial nephrectomy as a model for uremic cardiomyopathy in the mouse. Am J Physiol Renal Physiol. 2008;294:F450-F454.
20. Cooper CJ, Haller ST, Colyer W, Steffes M, Burket MW, Thomas WJ, Safian R, Reddy B, Brewster P, Ankenbrandt MA, Virmani R, Dippel E, Rocha-Singh K, Murphy TP, Kennedy DJ, Shapiro JI, D'Agostino RD, Pencina MJ, Khuder S. Embolic protection and platelet inhibition during renal artery stenting. Circulation. 2008;117:2752-2760.
21. Bagrov AY, Fedorova OV, Austin-Lane JL, Dmitrieva RI, Anderson DE. Endogenous marinobufagenin-like immunoreactive factor and Na +, K + ATPase inhibition during voluntary hypoventilation. Hypertension. 1995;26:781-788.
22. Fedorova OV, Simbirtsev AS, Kolodkin NI, Kotov AY, Agalakova NI, Kashkin VA, Tapilskaya NI, Bzhelyansky A, Reznik VA, Frolova EV, Nikitina ER, Budny GV, Longo DL, Lakatta EG, Bagrov AY. Monoclonal antibody to an endogenous bufadienolide, marinobufagenin, reverses preeclampsia-induced Na/K-ATPase inhibition and lowers blood pressure in NaCl-sensitive hypertension. J Hypertens. 2008;26:2414-2425.
23. Bagrov AY, Roukoyatkina NI, Pinaev AG, Dmitrieva RI, Fedorova OV. Effects of two endogenous Na +, K (+)-ATPase inhibitors, marinobufagenin and ouabain, on isolated rat aorta. Eur J Pharmacol. 1995;274:151-158.
24. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney functionmeasured and estimated glomerular filtration rate. N Engl J Med. 2006;354:2473-2483.
25. Fedorova OV, Talan MI, Agalakova NI, Lakatta EG, Bagrov AY. Endogenous ligand of α (1) sodium pump, marinobufagenin, is a novel mediator of sodium chloride-dependent hypertension. Circulation. 2002;105:1122-1127.
26. Dmitrieva RI, Bagrov AY, Lalli E, Sassone-Corsi P, Stocco DM, Doris PA. Mammalian bufadienolide is synthesized from cholesterol in the adrenal cortex by a pathway that is independent of cholesterol side-chain cleavage. Hypertension. 2000;36:442-448.
27. Bagrov AY, Shapiro JI, Fedorova OV. Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets. Pharmacol Rev. 2009;61:9-38.
28. Fedorova OV, Doris PA, Bagrov AY. Endogenous marinobufagenin-like factor in acute plasma volume expansion. Clin Exp Hypertens. 1998;20:581-591.
29. Liu ZQ, Ma AQ, Zhang L, Yang DY. Intra-cellular electrolyte changes and levels of endogenous digoxin-like substance within the plasma in patients with congestive heart failure. Int J Cardiol. 1990;27:47-53.
30. Manunta P, Maillard M, Tantardini C, Simonini M, Lanzani C, Citterio L, Stella P, Casamassima N, Burnier M, Hamlyn JM, Bianchi G. Relationships among endogenous ouabain, α-adducin polymorphisms and renal sodium handling in primary hypertension. J Hypertens. 2008;26:914-920.
31. Gonick HC, Ding Y, Vaziri ND, Bagrov AY, Fedorova OV. Simultaneous measurement of marinobufagenin, ouabain, and hypertensionassociated protein in various disease states. Clin Exp Hypertens. 1998;20:617-627.
32. Fedorova OV, Lakatta EG, Bagrov AY. Endogenous Na, K pump ligands are differentially regulated during acute NaCl loading of Dahl rats. Circulation. 2000;102:3009-3014.
33. Bagrov AY, Fedorova OV, Dmitrieva RI, French AW, Anderson DE. Plasma marinobufagenin-like and ouabain-like immunoreactivity during saline volume expansion in anesthetized dogs. Cardiovasc Res. 1996;31:296-305.
34. Liu J, Periyasamy SM, Gunning W, Fedorova OV, Bagrov AY, Malhotra D, Xie Z, Shapiro JI. Effects of cardiac glycosides on sodium pump expression and function in LLC-PK1 and MDCK cells. Kidney Int. 2002;62:2118-2125.
35. Periyasamy SM, Liu J, Tanta F, Kabak B, Wakefield B, Malhotra D, Kennedy DJ, Nadoor A, Fedorova OV, Gunning W, Xie Z, Bagrov AY, Shapiro JI. Salt loading induces redistribution of the plasmalemmal Na/K-ATPase in proximal tubule cells. Kidney Int. 2005;67:1868-1877.
36. Wollenweber J, Sheps SG, Davis GD. Clinical course of atherosclerotic renovascular disease. Am J Cardiol. 1968;21:60-71.
37. Isles C, Main J, O'Connell J, Brown I, Findlay J, Stewart R, Wilkinson R. Survival associated with renovascular disease in Glasgow and Newcastle: a collaborative study. Scott Med J. 1990;35:70-73.
38. Sheps SG, Osmundson PJ, Hunt JC, Schirger A, Fairbairn JF II. Hypertension and renal artery stenosis: seral observations on 54 patients treated medically. Clin Pharmacol Ther. 1965;6:700-709.
39. Valentine RJ, Clagett GP, Miller GL, Myers SI, Martin JD, Chervu A. The coronary risk of unsuspected renal artery stenosis. J Vasc Surg. 1993;18:433-439; discussion 439-440.
40. Conlon PJ, Little MA, Pieper K, Mark DB. Severity of renal vascular disease predicts mortality in patients undergoing coronary angiography. Kidney Int. 2001;60:1490-1497.
41. Dorros G, Jaff M, Mathiak L, Dorros II, Lowe A, Murphy K, He T. Four-year follow-up of Palmaz-Schatz stent revascularization as treatment for atherosclerotic renal artery stenosis. Circulation. 1998;98:642-647. (Pubitemid 28387490)
42. Johansson M, Herlitz H, Jensen G, Rundqvist B, Friberg P. Increased cardiovascular mortality in hypertensive patients with renal artery stenosis: relation to sympathetic activation, renal function and treatment regimens. J Hypertens. 1999;17:1743-1750.
43. MacDowall P, Kalra PA, O'Donoghue DJ, Waldek S, Mamtora H, Brown K. Risk of morbidity from renovascular disease in elderly patients with congestive cardiac failure. Lancet. 1998;352:13-16.
44. Bagrov AY, Agalakova NI, Kashkin VA, Fedorova OV. Endogenous cardiotonic steroids and differential patterns of sodium pump inhibition in NaCl-loaded salt-sensitive and normotensive rats. Am J Hypertens. 2009;22:559-563.
45. Bagrov YY, Manusova NB, Frolova EV, Egorova IA, Kashkin VA, Tapilskaya NI, Fedorova OV, Bagrov AY. Endogenous sodium pump inhibitors, diabetes mellitus and preeclampsia preliminary observations and a hypothesis. Pathophysiology. 2007;14:147-151.
46. Dostanic-Larson I, Van Huysse JW, Lorenz JN, Lingrel JB. The highly conserved cardiac glycoside binding site of Na, K-ATPase plays a role in blood pressure regulation. Proc Natl Acad Sci USA. 2005;102:15845-15850.
47. Fridman AI, Matveev SA, Agalakova NI, Fedorova OV, Lakatta EG, Bagrov AY. Marinobufagenin, an endogenous ligand of α-1 sodium pump, is a marker of congestive heart failure severity. J Hypertens. 2002;20:1189-1194.
48. Hamlyn JM, Ringel R, Schaeffer J, Levinson PD, Hamilton BP, Kowarski AA, Blaustein MP. A circulating inhibitor of (Na+ + K +) ATPase associated with essential hypertension. Nature. 1982;300:650-652.
49. Schoner W. Salt abuse: the path to hypertension. Nat Med. 2008;14:16-17.